JC04 Rec'd PCT/PTO 20 OCT 2005



PATENT Attorney Docket No. 056291-5207

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re A	Application of: Alan BARGE) Confirmation No. 5602
Appli	cation No.: 10/534,721) Group Art Unit: Unassigned
Intern	ational Appln. Filing Date: November 7, 2003) Examiner: Unassigned
For:	COMBINATION PRODUCT OF INHIBITOR OF THE SRC FAMILY ON NON-RECEPTOR TYROSINE KINASES AND GEMCITABINE)
	THE TREATMENT OF CANCER)

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Window
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir:

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Citation of Related U.S. Patent Applications

The Examiner's attention is directed to the following related co-pending U.S. patent applications:

Inventor	U.S. Serial No.	U.S. Patent No.	PCT Publication No.		
	Filing Date	Issue Date	PCT Publication Date		
Laurent François Andre	10/275,382		WO 01/94341		
Hennequin et al.	November 5, 2002		December 13, 2001		
Laurent François Andre	10/344,678		WO 02/016352		
Hennequin et al.	February 14, 2003		February 28, 2002		
Patrick Ple	10/533,931		WO 2004/041829		
	May 4, 2005		October 31, 2002		

A copy of the specification and claims for each application, in the form of the published PCT application from which such application was filed is being filed herewith.

<u>PLEASE DO NOT PRINT</u> the above information on the patent resulting from the subject application.

Consideration of each listed application is earnestly solicited since unpublished patent applications are contemplated as IDS material; see the exception in Rule 98(a)(2)(iii) and note the penultimate sentence of MPEP 609.

Further, in keeping with MPEP 609, Subsec. C(2), 2nd para., line 10 to end of the paragraph (especially note lines 18-25) PLEASE RETURN A COPY OF THIS LETTER with the Examiner's initials adjacent each above listing so that applicant will know that each listed application has been considered as required by PTO policy.

Citation of Documents

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants petition the Examiner to consider this Information Disclosure Statement and documents listed on the attached Form PTO-1449. To the best of the undersigned's knowledge, this Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced Application. Accordingly, Applicants do not believe a fee is due for filing this Supplemental Information Disclosure Statement.

Copies of the listed documents are attached. Applicants respectfully request that the Examiner initial and return the Form PTO-1449, indicating that the information has been considered and made of record herein.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If it should be determined that the listed documents constitute "prior art" under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such document.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

Attorney Docket No.: 056291-5207

Application No. 10/534,721

Page 3

Except for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or

credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a

CONSTRUCTIVE PETITION FOR EXTENSION OF TIME in accordance with 37 C.F.R.

§1.136(a)(3).

Respectfully Submitted,

Morgan Lewis & Bockius LL

Date:

October 20, 2005

Morgan Lewis & Bockius LLP

Customer No. 09629

1111 Pennsylvania Avenue, N.W.

Washington, D.C. 20004

Tel. No.: 202-739-3000

By:

Registration No. 25,3

Tel. No.: (202) 739-5320 Fax No.: (202) 739-3001

INFORMATION DISCLOSURE CITATION				Attorney Docket No. 056291-5207		Application No. 10/534,721				
(Use several sheets if necessary) PTO Form 1449				Applicants: Alan BARGE			PAGE 1 of 1			
				I. A	I. A. Filing Date: November 7, 2003		Group Art Unit: Unassigned			
S. PATENT DOCUMENTS										
Initial		Document No.	Date		Name	Class	Sub-Class	Filing Date		
FOREIGN PATENT DOCUMENTS										
		Document No.	Date		Country	Class	Sub-Class	Translation		
	1.	WO 01/94341	December 13, 200		WIPO					
	2	WO 02/092577	November 21, 200		WIPO					
	3	WO 02/092578	November 21, 200		WIPO					
	4.	WO 02/092579	November 21, 200		WIPO					
	5.	WO 02/16352	February 28, 200	2	WIPO		-			
	6.	WO 2004/032937	April 22, 2004		WIPO		-			
	7.	WO 2004/032939	April 22, 2004		WIPO		 			
	8.	WO 2004/041829	May 21, 2004		WIPO		 			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)										
	9.	Baker et al. (2002) "Blockade of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor Signaling for Therapy of Metastatic Human Pancreatic Cancer" Cancer Research 62: 1996-2003								
	10.	Bruns et al. (2000) "Blockade of the Epidermal Growth Factor Receptor Signaling by a Novel Tyrosine Kinase Inhibitor Leads to Apoptosis of Endothelial Cells and Therapy of Human Pancreatic Carcinoma" Cancer Res. 60(11):								
	11.	2926 - 2935 Duxbury et al. (2004) "Inhibition of Src tyrosine kinase impairs inherent and acquired gemcitabine resistance in human								
	12.	pancreatic adenocarcinoma cells" Clinical Cancer Research 10: 2307-2318 Yezhelyev et al. (2004) "Inhibition of Src Tyrosine Kinase as Treatment for Human Pancreatic Cancer Growing Orthotopically in Nude Mice" Clin. Cancer Res. 10(23): 8028-8036								
		Orthotopicany in reac	io whee emil. cancer	100	. 10(25). 0020 0050					
						_				
		·								
					· · · · · · · · · · · · · · · · · · ·					
	ļ									
	ļ		·					<u> </u>		
Examiner	Examiner Date Considered									
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.										